Search clinical trials for: Ruxolitinib 20 MG

Total 11480 results

Oncology Institute of Southern Switzerland

Withdrawn

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Prostate Cancer

Switzerland
Medicines for Malaria Venture
Nucleus Network Ltd; Southern Star Research Pty Ltd.

Completed

Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine

Malaria

Australia
Chinese PLA General Hospital

Completed

Low Dose Ruxolitinib in Combination With Methylprednisolone

Stem Cell Transplant Complications | aGVHD

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder
Eisai Co., Ltd.

Completed

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

Healthy Subjects

Japan
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Peking Union Medical College Hospital

Not yet recruiting

Avatrombopag Usage in NSAA

Drug Effect | Aplastic Anemia

China
Pfizer

Completed

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

Alopecia Areata

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Healthy

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

Dyslipidemias

Korea, Republic of
Tourmaline Bio, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease (spiriTED)

Thyroid Eye Disease

United States, Jordan
Xenon Pharmaceuticals Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (X-NOVA)

Major Depressive Disorder

United States
Instituto Nacional de Cancerologia de Mexico
Roche Pharma AG

Active, not recruiting

Tocilizumab Treatment in Patients With COVID-19

Sars-CoV2

Mexico
University of Utah

Completed

Remimazolam Sedation for Nerve Blocks (REMI-SEN)

Procedural Pain | Procedural Anxiety

United States
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
AstraZeneca

Completed

BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

Gastric Ulcer | Duodenal Ulcer | Reflux Esophagitis | Anastomotic Ulcer | Etc.

Japan
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
Intra-Cellular Therapies, Inc.

Not yet recruiting

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Healthy Volunteers

United States
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

Hypertension | Hyperlipidemias

Korea, Republic of
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Biogen

Terminated

A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Type 2 Diabetes | Chronic Kidney Disease
Takeda

Completed

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

Schizophrenia

United States
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Poland, Hungary, Denmark, Netherlands, Germany, Czechia, Portugal
Reata, a wholly owned subsidiary of Biogen

Withdrawn

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

Type 2 Diabetes Mellitus | End-Stage Renal Disease
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
University of Erlangen-Nürnberg Medical School
Bayer

Recruiting

Finerenone and Renal Oxidative Stress

Type2diabetes

Germany
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Estetra

Recruiting

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

Sexual Dysfunction, Physiological

United States
Neurim Pharmaceuticals Ltd.
Syneos Health

Active, not recruiting

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Healthy Volunteer

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
AstraZeneca

Completed

A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases

Zollinger-Ellison Syndrome | Reflux Esophagitis (RE) | Gastric Ulcer (GU) | Duodenal Ulcer (DU) | Anastomotic Ulcer (AU) | Non-erosive Reflux Esophagitis Disease (NERD)

Japan
Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
Jadran Galenski laboratorij d.d.

Completed

Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

Primary Open Angle Glaucoma of Both Eyes

Russian Federation
First Affiliated Hospital of Zhejiang University
Xiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaborators

Recruiting

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Hematologic Malignancy | Bronchiolitis Obliterans Syndrome

China
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Aegerion Pharmaceuticals, Inc.

Completed

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

Hypercholesterolemia

United States
Khon Kaen University
General Drugs House Co.,LTD.; Ubon Ratchathani Cancer Hospital, Ubon Ratchathani

Completed

Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients

Head and Neck Cancer

Thailand
Reata, a wholly owned subsidiary of Biogen

Terminated

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
ACO Hud Nordic AB
The University of Sheffield Medical School

Completed

A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier

Dermatitis, Atopic

United Kingdom
Cytokinetics
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

DLBCL | AML Including AML de Novo and AML Secondary to MDS
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States

Search clinical trials for: Ruxolitinib 20 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations